Business Context and Reporting Period
Company: Hercules Technology Growth Capital, Inc. (HTGC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2012
Business Overview: HTGC is an internally managed, non-diversified closed-end investment company regulated as a Business Development Company (BDC). It provides debt and equity growth capital to technology-related companies, including life science, clean technology, and lower middle market technology firms. The company operates as a Regulated Investment Company (RIC) for tax purposes.
Key Financial Metrics
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Total Assets | $763.4 million | $747.4 million (Dec 31, 2011) |
| Total Investments (at value) | $694.5 million | $652.9 million (Dec 31, 2011) |
| Net Investment Income | $11.4 million | $9.8 million |
| Net Realized Gains | $2.9 million | $4.4 million |
| Net Unrealized Appreciation | $2.9 million | $(15.4) million |
| Net Increase in Net Assets from Operations | $17.1 million | $(1.2) million |
| Net Asset Value (NAV) per Share | $9.76 | $9.20 |
| Weighted Average Shares Outstanding | 47.0 million | 42.7 million |
| Cash and Cash Equivalents | $48.4 million | $64.5 million (Dec 31, 2011) |
| Total Debt Outstanding | $271.4 million | $305.5 million (Dec 31, 2011) |
Debt Composition: Includes $200.8 million in SBA Debentures, $70.6 million in Convertible Senior Notes, and $0 in borrowings under the Wells and Union Bank facilities.
Material Changes vs. Prior Period
- Portfolio Growth: Total investment portfolio value increased by approximately $41.6 million (6.4%) from December 31, 2011, driven by new debt commitments of $42.6 million to new companies and $46.8 million to existing companies.
- Profitability Improvement: The company reported a net increase in net assets of $17.1 million, a significant turnaround from the $1.2 million decrease in the prior year quarter. This was primarily due to a shift from net unrealized depreciation of $15.4 million in Q1 2011 to net unrealized appreciation of $2.9 million in Q1 2012.
- Realized Gains: Net realized gains decreased to $2.9 million from $4.4 million in the prior year, largely due to fewer sales of public portfolio companies and the write-off of warrants in one private company.
- Capital Raise: In January 2012, the company completed a follow-on public offering of 5.0 million shares, raising approximately $48.1 million in gross proceeds.
- Debt Reduction: Total debt outstanding decreased by approximately $34.1 million compared to the prior year-end, primarily due to the repayment of $24.3 million in SBA debentures and the full payoff of the Wells Facility ($10.2 million).
Guidance, Outlook, and Risks
- Dividend Policy: On April 30, 2012, the Board increased the quarterly dividend by $0.01 to $0.24 per share, marking the 27th consecutive quarterly dividend. The company aims to distribute approximately 90-100% of taxable income.
- Subsequent Financing: In April 2012, the company issued $43.0 million of 7.00% Senior Notes due 2019, generating net proceeds of approximately $41.7 million.
- Portfolio Activity: As of May 8, 2012, the company had $45.0 million in closed commitments and $129.7 million in pending non-binding term sheets.
- Key Risks:
- Valuation Risk: Approximately 91% of assets are Level 3 investments valued by the Board of Directors, subject to significant judgment and potential volatility.
- Liquidity and Leverage: The company relies on SBA debentures and credit facilities. Failure to comply with SBA regulations or credit covenants could restrict borrowing or accelerate debt repayment.
- Concentration Risk: The ten largest portfolio companies represented approximately 37.9% of the total portfolio value. Specific concentrations include BrightSource Energy (7.5% of net assets) and Aveo Pharmaceuticals (6.1% of net assets).
- Interest Rate Risk: Approximately 91.1% of the loan portfolio is at variable rates, exposing the company to interest rate fluctuations.
Investor Verification Checklist
- Valuation Methodology: Verify the Board's fair value determinations for Level 3 assets, particularly in the Clean Tech and Drug Discovery sectors which comprise significant portions of the portfolio.
- SBA Compliance: Confirm continued compliance with Small Business Administration (SBA) regulations for HT II and HT III subsidiaries to ensure access to $225 million in guaranteed debentures.
- Debt Covenants: Monitor compliance with tangible net worth covenants under the Wells and Union Bank facilities, which increased following the January 2012 equity offering.
- Portfolio Concentration: Assess the financial health of top holdings (BrightSource Energy, Aveo Pharmaceuticals, Women's Marketing, Box.net) given their significant impact on NAV.
- Dividend Sustainability: Review the tax attributes of distributions to ensure they are supported by taxable income and not primarily returns of capital.